-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下:我們將AVY的目標股價從196美元下調至182美元,市盈率為15.9倍,低於AVY五年平均市盈率19.8倍,但高於競爭對手CCL Industries目前的18.1倍,這反映了AVY在2028年之前更強勁的每股收益增長以及調整後EBITDA利潤率的提升。我們將2026年每股收益預期從10.23美元小幅上調至10.27美元,以反映其第一季業績超出預期(我們維持2027年每股收益預期為11.46美元)。 AVY第一季業績表現強勁,展現了其多元化投資組合在充滿活力且充滿挑戰的宏觀經濟環境下的穩健實力。由於材料集團的強勁表現,AVY的獲利和營收均超出預期,抵銷了解決方案集團銷售額較去年同期下降3%的影響。管理層表示,由於石化產品價格上漲,3月原物料價格顯著上漲。 AVY預計第二季季通膨率將達到高個位數,並已採取措施漲價以應對通膨。我們認為,原物料價格上漲以及地緣政治的不確定性可能會對下半年的需求產生影響。
Related Articles
Argus Adjusts Price Target on Nasdaq to $103 From $98
Nasdaq (NDAQ) has an average rating of buy and mean price target of $110.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $91.54, Change: $-0.37, Percent Change: -0.40%
Argus Adjusts Price Target on IDEX to $250 From $240
IDEX (IEX) has an average rating of overweight and mean price target of $236.46, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $214.86, Change: $-2.99, Percent Change: -1.37%
Argus Adjusts Price Target on Thermo Fisher Scientific to $560 From $610
Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $623.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $470.05, Change: $-8.91, Percent Change: -1.86%